Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Pharmaceuticals

Market Closed - Japan Exchange 07:00:00 12/09/2024 BST 5-day change 1st Jan Change
8,189.00 JPY +0.40% Intraday chart for Otsuka Holdings Co., Ltd. -1.18% +54.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Adjusts Otsuka Holdings' Price Target to 9,700 Yen From 9,300 Yen, Keeps at Buy MT
Jefferies Adjusts Otsuka Holdings' Price Target to 9,300 Yen From 8,600 Yen, Keeps at Buy MT
Otsuka's Profit Up 5% in Fiscal H1 MT
Global markets live: Shell, Chevron, Boeing, Walt Disney, Qualcomm... Our Logo
Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Announces Second Quarter-End Dividend for the Six Months Ended June 30, 2024, Payable on September 2, 2024 CI
Transcript : Otsuka Holdings Co., Ltd., Q2 2024 Earnings Call, Aug 01, 2024
Otsuka Holdings Co., Ltd. announces an Equity Buyback for 10,000,000 shares, representing 1.84% for ¥50,000 million. CI
Otsuka Holdings Co., Ltd. authorizes a Buyback Plan. CI
Jefferies Adjusts Otsuka Holdings' Price Target to 8,600 Yen From 8,100 Yen, Keeps at Buy MT
Nikkei Rises Ends Eight-Session Losing Streak on Monetary Tightening Bets MT
Otsuka Revises H1 Financial Outlook Upward MT
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2024 CI
Jefferies Adjusts Otsuka Holdings' Price Target to 8,100 Yen From 7,800 Yen, Keeps at Buy MT
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9) RE
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches MT
Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application MT
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder CI
Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026 CI
Correction: Otsuka Pharmaceutical's PTSD Treatment Candidate Sees Statistically Significant Results in Two Out of Three Trials MT
Japanese Shares Close Lower as JGB Yields Hit 12-Year High MT
Otsuka Pharmaceutical's PTSD Treatment Candidate Fails to Meet Primary Endpoint in Phase 3 Trial MT
Jefferies Adjusts Otsuka Holdings' Price Target to 7,800 Yen From 7,400 Yen, Keeps at Buy MT
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1 MT
Chart Otsuka Holdings Co., Ltd.
More charts
Logo Otsuka Holdings Co., Ltd.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Employees
34,388
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
8,156.00JPY
Average target price
8,259.09JPY
Spread / Average Target
+1.26%
Consensus
  1. Stock Market
  2. Equities
  3. 4578 Stock
  4. News Otsuka Holdings Co., Ltd.
  5. Otsuka's Unit Remains as MicroPort Scientific's Thai Distributor Until 2026
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW